<IPO>Hengrui Pharma (600276.SH)'s HK IPO Gets Filing Notice from CSRC; Rumor Says Fundraising USD2B
Hengrui Pharma (600276.SH) has received a filing notice from the China Securities Regulatory Commi...
Hengrui Pharma (600276.SH) has received a filing notice from the China Securities Regulatory Commission (CSRC) for its overseas listing, planning to issue up to 815.0946 million ordinary shares for listing on the Hong Kong Stock Exchange.
Hengrui Pharma's IPO in Hong Kong may take place this year, potentially raising USD2 billion, with Morgan Stanley, Citigroup, and Huatai Securities being the joint sponsors for this IPO, Bloomberg quoted people familiar with the matter.
In 1Q25, Hengrui Pharma's revenue leaped 20% YoY to RMB7.206 billion, with net profit attributable to the parent company adding nearly 37% to RMB1.874 billion.
(A Shares quote is delayed for at least 15 mins.)
Disclaimer: The views in this article are from the original Creator and do not represent the views or position of Hawk Insight. The content of the article is for reference, communication and learning only, and does not constitute investment advice. If it involves copyright issues, please contact us for deletion.
